Nicole R Fowler1,2,3,4, Anthony J Perkins5, Sujuan Gao5, Greg A Sachs1,2,3, Malaz A Boustani1,2,3,4. 1. Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana. 2. Indiana University Center for Aging Research, Indianapolis, Indiana. 3. Regenstrief Institute, Inc, Indianapolis, Indiana. 4. Center for Health Innovation and Implementation Science, Indiana Clinical and Translational Science Institute, Indianapolis, Indiana. 5. Department of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana.
Abstract
BACKGROUND/ OBJECTIVE: The benefits and harms of screening of Alzheimer disease and related dementias (ADRDs) are unknown. This study addressed the question of whether the benefits outweigh the harms of screening for ADRDs among older adults in primary care. DESIGN, SETTING, AND PARTICIPANTS: Single-blinded, two-arm, randomized controlled trial (October 2012-September 2016) in urban, suburban, and rural primary care settings in Indiana. A total of 4005 primary care patients (aged ≥65 years) were randomized to ADRD screening (n = 2008) or control (n = 1997). INTERVENTION: Patients were screened using the Memory Impairment Screen or the Mini-Cog and referred for a voluntary follow-up diagnostic assessment if they screened positive on either or both screening tests. MEASUREMENTS: Primary measures were health-related quality of life (HRQOL; Health Utilities Index) at 12 months, depressive symptoms (Patient Health Questionnaire-9), and anxiety symptoms (Generalized Anxiety Disorder seven-item scale) at 1 month. RESULTS:The mean age was 74.2 years (SD = 6.9 years); 2257 (66%) were female and 2301 (67%) were white. At 12 months, we were unable to detect differences in HRQOL between the groups (effect size = 0.009 [95% confidence interval {CI} = -0.063 to 0.080]; P = .81). At 1 month, differences in mean depressive symptoms (mean difference = -0.23 [90% CI = -0.42 to -0.039]) and anxiety symptoms (mean difference = -0.087 [90% CI = -0.246 to 0.072]) were within prespecified equivalency range. Scores for depressive and anxiety symptoms were similar between the groups at all time points. No differences in healthcare utilization, advance care planning, and ADRD recognition by physicians were detected at 12 months. CONCLUSION: We were unable to detect a difference in HRQOL for screening for ADRD among older adults. We found no harm from screening measured by symptoms of depression or anxiety. Missing data, low rates of dementia detection, and high rate of refusal for follow-up diagnostic assessments after a positive screen may explain these findings. J Am Geriatr Soc 68:535-543, 2020.
RCT Entities:
BACKGROUND/ OBJECTIVE: The benefits and harms of screening of Alzheimer disease and related dementias (ADRDs) are unknown. This study addressed the question of whether the benefits outweigh the harms of screening for ADRDs among older adults in primary care. DESIGN, SETTING, AND PARTICIPANTS: Single-blinded, two-arm, randomized controlled trial (October 2012-September 2016) in urban, suburban, and rural primary care settings in Indiana. A total of 4005 primary care patients (aged ≥65 years) were randomized to ADRD screening (n = 2008) or control (n = 1997). INTERVENTION: Patients were screened using the Memory Impairment Screen or the Mini-Cog and referred for a voluntary follow-up diagnostic assessment if they screened positive on either or both screening tests. MEASUREMENTS: Primary measures were health-related quality of life (HRQOL; Health Utilities Index) at 12 months, depressive symptoms (Patient Health Questionnaire-9), and anxiety symptoms (Generalized Anxiety Disorder seven-item scale) at 1 month. RESULTS: The mean age was 74.2 years (SD = 6.9 years); 2257 (66%) were female and 2301 (67%) were white. At 12 months, we were unable to detect differences in HRQOL between the groups (effect size = 0.009 [95% confidence interval {CI} = -0.063 to 0.080]; P = .81). At 1 month, differences in mean depressive symptoms (mean difference = -0.23 [90% CI = -0.42 to -0.039]) and anxiety symptoms (mean difference = -0.087 [90% CI = -0.246 to 0.072]) were within prespecified equivalency range. Scores for depressive and anxiety symptoms were similar between the groups at all time points. No differences in healthcare utilization, advance care planning, and ADRD recognition by physicians were detected at 12 months. CONCLUSION: We were unable to detect a difference in HRQOL for screening for ADRD among older adults. We found no harm from screening measured by symptoms of depression or anxiety. Missing data, low rates of dementia detection, and high rate of refusal for follow-up diagnostic assessments after a positive screen may explain these findings. J Am Geriatr Soc 68:535-543, 2020.
Authors: Tracey Holsinger; Brenda L Plassman; Karen M Stechuchak; James R Burke; Cynthia J Coffman; John W Williams Journal: J Am Geriatr Soc Date: 2012-05-30 Impact factor: 5.562
Authors: B L Plassman; K M Langa; G G Fisher; S G Heeringa; D R Weir; M B Ofstedal; J R Burke; M D Hurd; G G Potter; W L Rodgers; D C Steffens; R J Willis; R B Wallace Journal: Neuroepidemiology Date: 2007-10-29 Impact factor: 3.282
Authors: Nicole R Fowler; Amie Frame; Anthony J Perkins; Sujuan Gao; Dennis P Watson; Patrick Monahan; Malaz A Boustani Journal: Alzheimers Dement (Amst) Date: 2015-06
Authors: Halima Amjad; Quincy M Samus; Jin Huang; Sneha Gundavarpu; Julie P W Bynum; Jennifer L Wolff; David L Roth Journal: J Am Geriatr Soc Date: 2021-11-13 Impact factor: 5.562
Authors: David F Tang-Wai; Eric E Smith; Marie-Andrée Bruneau; Amer M Burhan; Atri Chatterjee; Howard Chertkow; Samira Choudhury; Ehsan Dorri; Simon Ducharme; Corinne E Fischer; Sheena Ghodasara; Nathan Herrmann; Ging-Yuek Robin Hsiung; Sanjeev Kumar; Robert Laforce; Linda Lee; Fadi Massoud; Kenneth I Shulman; Michael Stiffel; Serge Gauthier; Zahinoor Ismail Journal: Alzheimers Dement (N Y) Date: 2020-11-11
Authors: Michael J Kleiman; Abbi D Plewes; Arthur Owora; Randall W Grout; Paul Richard Dexter; Nicole R Fowler; James E Galvin; Zina Ben Miled; Malaz Boustani Journal: Trials Date: 2022-10-11 Impact factor: 2.728
Authors: Gill Livingston; Jonathan Huntley; Andrew Sommerlad; David Ames; Clive Ballard; Sube Banerjee; Carol Brayne; Alistair Burns; Jiska Cohen-Mansfield; Claudia Cooper; Sergi G Costafreda; Amit Dias; Nick Fox; Laura N Gitlin; Robert Howard; Helen C Kales; Mika Kivimäki; Eric B Larson; Adesola Ogunniyi; Vasiliki Orgeta; Karen Ritchie; Kenneth Rockwood; Elizabeth L Sampson; Quincy Samus; Lon S Schneider; Geir Selbæk; Linda Teri; Naaheed Mukadam Journal: Lancet Date: 2020-07-30 Impact factor: 79.321